Abbott Q2 beat puts ABT stock in focus as guidance rises
Abbott Laboratories beat second-quarter expectations and raised its full-year 2026 adjusted profit guidance, putting ABT stock back in the spotlight. Sales reached $12.59 billion, up 13%, while adjusted EPS hit $1.31. The company lifted its adjusted EPS outlook to $5.45–$5.60 from $5.38–$5.58, citing broad-based growth led by diagnostics and medical devices.
Key Takeaways
- Q2 net sales rose 13.0% to $12.59 billion, with comparable sales growth of 4.8%.
- Adjusted diluted EPS was $1.31; GAAP diluted EPS was $0.53.
- Full-year 2026 adjusted EPS guidance moved to $5.45–$5.60 from $5.38–$5.58.
- Comparable sales growth guidance of 6.5%–7.5% was reaffirmed.
- Diagnostics reported sales jumped 42.3%, helped by the Exact Sciences deal.
For readers tracking health-tech and diagnostics innovation in our Future Tech & AI Wonders coverage, Abbott’s update ties earnings momentum to wearables, cancer screening tools, and device pipelines.
What did Abbott report for Q2 2026?
Abbott said second-quarter sales increased 13.0% on a reported basis and 4.8% on a comparable basis. Adjusted diluted EPS of $1.31 excludes specified items, while GAAP diluted EPS came in at $0.53.
According to Abbott’s official results release, the company returned $2.1 billion to shareholders in the quarter through dividends and share repurchases.
Chairman and CEO Robert B. Ford said second-quarter results “reflect the momentum we are building,” adding that Abbott expects accelerating sales and earnings growth in the second half of the year.
Why did diagnostics help drive the sales rise?
Worldwide Diagnostics sales rose 42.3% on a reported basis and 2.9% on a comparable basis. The large reported jump reflects Abbott’s March 23, 2026, acquisition of Exact Sciences, now presented as Cancer Diagnostics.
Cancer Diagnostics comparable growth was 13.3%, with mid-teens growth in Cologuard as new and repeat users expanded. Core Laboratory Diagnostics grew on strength in the U.S. and Latin America, while Rapid and Molecular Diagnostics lagged on lower respiratory virus test sales.
Medical Devices sales rose 9.0% reported and 8.4% comparable, led by electrophysiology, rhythm management, diabetes care, and heart failure. Continuous glucose monitor sales grew 11.0% reported and 9.5% comparable. Established Pharmaceuticals rose 8.4% reported and 8.7% comparable. Nutrition sales fell 3.1% reported.
What does the raised guidance mean for ABT stock watchers?
Abbott reaffirmed full-year 2026 comparable sales growth of 6.5% to 7.5% and raised adjusted diluted EPS guidance to $5.45 to $5.60, from $5.38 to $5.58. That higher profit band is the clearest signal for ABT stock investors scanning the print.
Pipeline and product news also kept a future-tech thread in the quarter: CE Mark for Libre Duo, a dual glucose-ketone biowearable; enrollment completion in the TECTONIC U.S. pivotal trial for an investigational coronary intravascular lithotripsy system; and an FDA submission for the Amulet 360 left atrial appendage device.
Bottom line: the beat-and-raise package, plus diagnostics and devices growth, explains why ABT stock is drawing fresh attention after the Q2 report.